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Abstract  
Background: There are few studies on the impact of glioma surgery on health-related quality 
of life (HRQoL). The generic instrument EQ-5D 3L has been utilized in this context, but 
several questions concerning use and interpretation are unanswered. 
Objective: To evaluate the responsiveness of EQ-5D 3L in patients undergoing glioma 
surgery and estimate the minimal clinically important difference (MID). 
Materials and methods: EQ-5D 3L index values from 164 patients who underwent glioma 
surgery in the period 2007-2012 were analysed. Responsiveness and MID were estimated by 
using a combination of distribution-based and anchor-based methods. Karnofsky Performance 
Status (KPS) served as an anchor.  
Results: Patients who improved functionally did not report significantly higher EQ-5D 3L 
scores postoperatively with a Standardized Response Mean (SRM) of 0.04 (p=0.13). Patients 
who deteriorated functionally reported significantly lower EQ-5D 3L scores postoperative 
with a SRM of 0.72 (p <0.001). With different approaches we determined a range of MID-
values from 0.07 to 0.15. 
Conclusions: EQ-5D 3L is responsive to changes when glioma patients are deteriorating 
functionally after surgery but not responsive when the patients are improving. The MID-
values for EQ-5D 3L in glioma surgery are in the upper range of reported MID-values for 
other conditions. 
Relevance 
Knowledge of EQ-5D 3Ls ability to detect changes is important when planning and designing 
HRQoL-studies. The MID-value is useful for calculating statistical power, for determining 
sample sizes and for interpreting results. 
Keywords  
Glioma - Outcome - Quality of life - EQ-5D - MID - Responsiveness 
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1. Theoretical background 
1.1 Glioma surgery 
1.1.1 Diffuse gliomas 
Gliomas are the most common entity among primary brain tumours, representing 
approximately 30% (1). They arise from the glial cells and are named after the specific type of 
cell they resemble the most histopathologically, i.e. astrocytes (astrocytomas), 
oligodendrocytes (oligodendrogliomas) or ependymal cells (ependymomas) (1, 2). Except for 
male gender and radiation exposure, there are no known and established risk factors (3, 4). 
Gliomas can be classified as low-grade (grade I-II) or high-grade (grade III-IV) according to 
the WHO-classification (5), where higher grades are associated with worse prognoses. Diffuse 
grade II-IV gliomas can usually not be cured due to infiltrative growth (6) and represent the 
great majority of gliomas (1). These (WHO grade II-IV) are the entities included in the 
present work.  
The diffuse low-grade gliomas (WHO grade II) grow slowly and include grade II 
astrocytoma, oligodendroglioma and oligoastrocytoma (mixed glioma) (5). Together, the 
incidence rate is around 5 cases per million per year (7), and is consequently a rare disease. 
Low-grade gliomas usually affect younger patients and median age at diagnosis is around 40-
45 years (1, 8). They often demonstrate continuous growth and there is a tendency towards 
progression to higher grades of malignancy with time (9).  
High-grade gliomas are fast growing diffusely infiltrating tumours that may metastasize 
within the brain (6). They include anaplastic glioma (grade III) and glioblastoma (grade IV) 
(5). The incidence rate is approximately 5 cases per 100 000  per year (2). Glioblastoma is the 
most common type, accounting for about 50% of all gliomas (1). The primary form (i.e. not 
transformed from low-grade gliomas) most commonly affects older adults, with a median in 
the 6
th
 decade of life (1).  
1.1.2 Clinical signs 
Diffuse gliomas may cause diverse symptoms depending on which part of the brain that is 
affected (10). The symptoms may occur quickly, but a slow-growing tumour may also be 
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asymptomatic and detected as an incidental finding during brain imaging done for other 
reasons (9). 
Focal symptoms like motor deficits (paresis), loss of sensations, visual deficits, speech 
problems (aphasia, dysphasia), personality change and cognitive deficits can occur, alone or 
in combination. They are caused by the tumours local effect on the closest adjacent structures. 
The tumour can also cause symptoms due to a mass effect with increased intracranial pressure 
due to the expanding tumour, cerebral oedema and/or obstructive hydrocephalus. This leads to 
progressive general symptoms like headache, nausea and vomiting. In pronounced cases, this 
will also affect the level of consciousness (2, 10). Another frequent symptom, especially in 
low-grade gliomas (11), is epileptic seizures caused by disorganized electrical activity in the 
brain. 
1.1.3 Diagnosis 
An imaging scan of the brain, either magnetic resonance imaging (MRI) or computed 
tomography (CT) will usually be carried out based on the patient’s symptoms. This imaging 
can be combined with functional MR, MR diffusion imaging, MR perfusion studies and/or 
with proton MR spectroscopy. However, such non-invasive investigations are not sufficiently 
specific and a biopsy is with few exceptions required to ensure a correct diagnosis (12). 
1.1.4 Surgery 
As diffuse gliomas grow infiltrative, the possibility of radical surgical removal is limited and 
glioma surgery rarely results in cure since remaining tumour cells continue to grow (2). 
Resection of all visible tumour tissue, i.e. gross total resection (GTR), is nevertheless 
associated with improved survival in high-grade gliomas (13, 14). In low-grade gliomas the 
role of surgery has earlier been somewhat controversial (12, 15), but there is now strong 
evidence in support of early and extensive resections in most patients (16, 17).  Repetitive 
surgery for recurrent glioma is a common strategy (10, 17, 18), although not supported by 
hard evidence. Thus, surgery is a cornerstone in the modern treatment and also a necessity to 
obtain a diagnostic biopsy (12).  
A key factor for deciding on a strategy regarding the planned extent of resection is the 
anatomical localization of the lesion. Certain regions of the brain are considered particularly 
important and are called eloquent areas. These include areas associated with speech, motor, 
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and visual functions (19). Surgery in relation to these areas is associated with an increased 
risk of neurological deficits. Tumours can also invade critical structures such as crucial blood 
vessels, the brain stem or cranial nerves, increasing the difficulty of safe removal. Thus, 
glioma surgery is a delicate balance between removal of as much tumour as possible while 
avoiding neurologic deficits or adverse effects.  
Several tools are available to optimize the safety of the surgical procedure, such as 
intraoperative MRI, intraoperative 3D ultrasound, fluorescence-guiding and/or awake-surgery 
(12, 20-23).  GTR is a treatment goal when technically feasible without jeopardizing 
neurological functions (12). If the tumour cannot be completely excised, the symptoms of 
mass effect might be reduced by removal of a part of the tumour, i.e. surgical debulking or 
cytoreductive surgery (2). Sometimes, obtaining only a biopsy can be the preferred strategy 
due to risk factors like unfavourable location of the tumour, poor general health, poor 
functional status and advanced age of the patient (12).  
1.1.5 Other treatments 
Glioma treatment is often a combined approach, based on symptom management, surgery, 
and often adjuvant therapy in terms of radiotherapy and/or chemotherapy (12).  
Symptom management is commonly initiated preoperatively. Cerebral oedema can be treated 
with corticosteroids, epileptic seizures with anti-seizure medications (2, 12) and obstructive 
hydrocephalus may require cerebrospinal fluid diversion procedure to bypass the blockage 
and lower the pressure within the brain (10, 12).   
The choice of adjuvant therapy largely depends on the histopathological classification and is 
for the most part reserved for patients with high grade gliomas (12). Conventional fractioned 
radiotherapy in combination (concomitant) with chemotherapy, usually Temozolomide, is 
normally offered to functionally independent patients (10, 12, 24). The adjuvant treatment is 
usually well tolerated, but may sometimes also have unwanted side effects. Hematologic toxic 
effects with subsequent infections, fatigue, thromboembolic events, nausea/vomiting, skin 
reactions and hair loss may occur during treatment (25-27). In addition, cerebral radiation 
therapy can result in long term side effects in form of cognitive deficits (28). 
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1.1.6 Survival and risks of surgery 
Gliomas have a major impact on survival. In addition to tumour grade (WHO I-IV) and extent 
of surgical resection, age and Karnofsky Performance Status (KPS) (29), a clinician rated 
functional health status, are established and important prognostic factors (14). The 10-year 
survival rate for low-grade gliomas is reported from 36-63 % and oligodendrogliomas have a 
slight better prognosis than astrocytomas (1, 8). High-grade gliomas have a much poorer 
prognosis. In unselected population-based materials, the median survival is 2-3 years for 
patients with anaplastic glioma (5) and less than a year for patients with glioblastoma (5, 30). 
Older patients have an even worse prognosis with a median survival of 104 days after 
diagnosis in age >75 years (31).  
New or worsened neurological deficits is reported in 9-36% of the patients after glioma 
surgery (20, 21, 24, 30, 32-38). Some deficits are transient due to manipulation during surgery 
and may regress spontaneously or following to training and rehabilitation. Other surgical 
complications such as infections, postoperative bleedings and CSF-leaks occur in 7-19 % (20, 
37-39).  
1.2 Aspects of health-related quality of life  
1.2.1 Definitions 
“Quality of life” (QoL) has no universally accepted definition. The concept is 
multidimensional, subjective and related to society (40). Thereby, the understanding of 
quality of life is both a philosophical and scientific question. However, there are extensive 
definitions available. A commonly used definition derives from the World Health 
Organization (41), which defines quality of life as; 
“an individual’s perception of their position in life in the context of the culture and 
values systems in which they live and in relation to their goals, expectations, 
standards and concerns. It is a broad ranging concept affected in a complex way by 
the person's physical health, psychological state, level of independence, social 
relationships, and their relationships to salient features of their environment”  
“Health-related quality of life” (HRQoL) is a term differentiating between quality of life in 
general, and those aspects that are relevant to the health. It can be defined as "The extent to 
which one’s usual or expected physical, emotional and social well-being is affected by a 
medical condition or its treatment" (42).  
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1.2.2 HRQoL as an outcome  
In brain surgery, outcome assessments have traditionally focused on survival, extents of 
resection, complications and functional health status. Such outcome measures are naturally of 
importance in evaluating the effectiveness of surgery, but may potentially be affected by 
assessment and interest bias when operating surgeons or health professionals evaluate the 
result of their own clinical work (43). There are no universally embraced and accepted scales 
for assessing side effects from brain surgery and reported results vary much between 
publications. Also, conventional outcome measures do not assess patients’ “wellbeing” 
properly, since their own, subjective evaluation of their health status is not taken into account. 
HRQoL is a patient-reported outcome (PRO), which means that it is measured from the 
patient’s perspective. PROs often differ substantially from the judgment of health 
professionals (40, 44, 45). Quality of life includes many subjective elements, and health 
professionals may not have the necessary knowledge of the patient’s feelings to evaluate their 
quality of life accurately (44). Health professionals tend to underestimate their symptoms (46) 
or severely or fatally ill patients may accept disadvantages for the prospect of minimal 
benefit, contrary to the expectations of health professionals (40). Since glioma surgery is a 
palliative treatment, HRQoL measurements are highly relevant measures of outcome. The 
benefits of extended survival and/or progression delay have to be carefully balanced against 
potential negative impact on HRQoL (47). 
1.2.3 HRQoL instruments 
HRQoL can be measured by using generic (i.e. general) instruments or so-called disease-
specific instruments. Generic instruments focus on broad aspects of HRQoL and are intended 
for use in general populations or across a wide range of disease conditions. These instruments 
are useful when comparing results from a HRQoL-study with data from other groups of 
patients and/or in health economic assessments. Disease-specific instruments are developed to 
detect more subtle disease- and treatment-related effects and are usually more sensitive than 
generic instruments (48). Since HRQoL is a complex construct, both instruments consist of 
many items. One single item can measure a simple aspect of HRQoL, such as physical 
symptom. In more complex concepts, several questions can be combined to form a multi-item 
scale. Some instruments are designed such that all items are combined together, and averaged 
to an overall score for HRQoL (49). 
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1.2.4 HRQoL in glioma patients 
Scoring the patients functional status using KPS was one of the first instruments in use for 
QoL measurements in cancer (40) and also in brain tumour patients (50). The development of 
a multidimensional patient reported HRQoL instrument for self-assessment was built upon 
KPS (40) and emerged in the early 1990s in the medical oncology literature (51). Since then, 
HRQoL has become increasingly used as an outcome measure in clinical trials evaluating 
oncological glioma treatment (47, 51, 52).  
The most common instrument that has been used in glioma patients is the disease-specific 
instrument EORTC-QLQ-C30 (47, 52, 53). This instrument has often been combined with a 
domain-specific instrument, EORTC QLQ-BN20, which is specifically developed and 
evaluated for brain tumour patients undergoing radio- and chemotherapy (54). This entire 
questionnaire package contains of 50 questions, where some are more or less repeated in 
different forms. Without exception, trials with the EORTC-instruments have focused on 
effects and side effects of the adjuvant treatment and baseline data has been collected after 
surgery (55-58).  
1.2.5 HRQoL in glioma surgery 
Patient-reported HRQoL as an outcome measure in glioma surgery is still uncommon and no 
disease-specific instruments have so far been developed for use in this context. To our 
knowledge, only a few studies have evaluated the effect of surgery on HRQoL and two of 
them have recently been published from our institution (59, 60). In these studies, there was a 
need for a simple and practical instrument that also allows for health economic evaluations. 
Thus, the generic instrument EQ-5D 3L was utilized. The findings in these studies indicate 
that new surgical acquired deficits have a major undesirable effect on HRQoL (59) and that 
deterioration in HRQoL shortly after surgery is independently and markedly associated with 
impaired survival (60). Thus, EQ-5D 3L may be a fairly good and practical outcome measure 
in glioma patients since it is both responsive to adverse events and has prognostic properties.  
A more detailed presentation of EQ-5D 3L is presented below, in the chapter “Materials and 
methods”.   
 
8 
 
1.2.6 Responsiveness and minimal clinically important difference 
To be clinically useful, HRQoL-instruments need to demonstrate validity and reliability. This 
means that the instrument measures what it is intended to measure and the results are 
reproducible and consistent. However, in QoL research, scales are subjective in nature and 
can never be proved to be universally valid and applicable. The process of validation is 
therefore a never-ending task. When using a HRQoL-instrument in a new clinical setting, 
additional testing is required (61).  
Responsiveness to change is an aspect of validity (62, 63) that is important when using 
HRQoL-instruments for evaluative purposes (61). This property relates to the instruments 
ability to detect meaningful change over time (61, 64, 65). A HRQoL-instrument should 
preferably respond to changes both when the patients’ overall QoL improves and when it 
deteriorates (61).  
Knowledge of the instrument’s responsiveness to change is not sufficient. It is also important 
to know whether the measured changes are important for the patients. Clinical meaningful 
change is often termed “minimal clinically important difference” (MCID or MID) (46, 64-66). 
MID has been defined as “the smallest difference in score in the domain of interest that 
patients perceive as important, either beneficial or harmful, and which would lead the 
clinician to consider a change in the patient's management” (67). An estimate of this score is 
helpful for calculating sample sizes and present results in simple categories, such as the 
number of patients experiencing meaningful change after treatment (62, 68). MID is also 
helpful for interpreting results from HRQoL-studies since HRQoL results most often are not 
intuitive. Many clinicians are unfamiliar with various scale values and summary scores 
followed by p-values. Highly statistically significant p-values do not indicate that the changes 
are clinically significant and thereby meaningful for the patients. In studies with large sample 
sizes, even a very small difference in HRQoL can be detected and found to be statistically 
significant. Conversely, in small sample sizes, a non-significant difference may still be 
important in clinical terms (69). 
The extent of change in HRQoL-scores will depend on its starting point (i.e. baseline) and this 
is an important issue to consider when measuring change. A patient with a good HRQoL may 
never demonstrate improvement if the baseline score on the instrument already is at the 
highest point (i.e. the ceiling effect). Nor will a patient with a poor health status experience 
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further deterioration if the score is at the lowest point at baseline (i.e. the floor effect). Such 
floor- and ceiling effects may be of particular importance when using generic instruments (70, 
71). 
For estimating responsiveness and MID, it has been recommended to use a combination of 
distribution-based and anchor-based methods (66, 72). Distribution-based methods are based 
on statistical characteristics of the sample. Anchor-based methods rely on examining the 
associations between scores of the instrument and an external anchor that clinicians can easily 
interpret. Often both approaches are combined, and anchor-based changes are further explored 
with distribution-based methods (70). Anchors should be chosen based on the relevance for 
the disease, clinical acceptance and validity and evidence that the anchors have some 
relationship with the measure (72). Responsiveness and MID can be determined using cross-
sectional and/or longitudinal analyses (70, 73-75). Since there is no single best method for 
estimating MIDs, the use of multiple strategies simultaneously has been recommended (68, 
72, 76). 
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2. Introduction  
Diffuse gliomas are the most common primary brain tumours (5). Surgery, although a 
cornerstone in modern treatment, is no cure since gliomas infiltrate the brain diffusely. 
Maximal tumour resection is associated with extended survival (13, 14, 16, 17), but there is a 
considerable risk of both neurological deficits and adverse effects. Thus, the benefits have to 
be carefully weighed against the potential negative side effects of the surgery in a given 
patient.  
To better understand the impact of surgery as experienced by the patients, health-related 
quality of life (HRQoL) is highly relevant and is gaining acceptance as an important adjunct 
to the traditional functional outcome scales scored by health professionals. However, such 
measures are still very uncommon in surgical brain tumour research and there are today no 
HRQoL-instruments specifically designed or validated for use in this clinical setting. 
In some recent publications, the generic HRQoL instrument EQ-5D 3L (77) has been utilized 
to evaluate the effect of glioma surgery (59, 60). However, there are several unanswered 
questions concerning use and interpretation of this outcome parameter in this context. In order 
to apply EQ-5D 3L for evaluative purposes, knowledge of its ability to detect change over 
time is important, i.e. responsiveness (61, 64, 65). In addition, clinicians should be able to 
easily interpret whether the measured changes are of importance for the patients, i.e. “minimal 
clinically important difference” (MID) (66, 69). 
The objectives of the present study were therefore (1); to evaluate the responsiveness for EQ-
5D 3L in patients undergoing glioma surgery, and (2); to estimate a range of MID-values for 
EQ-5D 3L index value in glioma patients. 
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3. Materials and methods 
3.1 Study design 
In this prospective registry-based study, a combination of anchor-based and distribution-based 
methods were used to estimate responsiveness and MID for EQ-5D 3L, as recommended (68, 
72). Karnofsky Performance Status (KPS) served as an anchor and both longitudinal and 
cross-sectional data were analysed. 
3.2 Study population 
In the present study, we were able to include 164 of 346 patients (47 %) aged ≥18 years that 
underwent surgery for supratentorial gliomas at St.Olavs University Hospital from January 
2007 through August 2012. A flow chart of the inclusion process is shown in Figure 1. The 
reasons for non-inclusion were only registered in the period from September 2011 through 
August 2012 (n=67). The patients were either not found eligible due to severe cognitive 
deficits (n=3/67, 4 %), severe illness (n=3/67, 4 %), due to non-consent (n=6/67, 9 %), or 
missed due to administrative reasons (n=3/67, 4%). Patients with infratentorial gliomas were 
excluded (n=9). Three patients (2%) were dead at scheduled follow up and 19 (12%) were lost 
to follow-up. Follow-up data was available from 142 patients (87 %). There was four missing 
item within a single form and imputation was done by using sample mean imputation (78).   
  
173 patients gave their written and informed consent 
 
9 patients with 
infratentorial gliomas 
excluded 
  
 
164 patients with supratentorial gliomas included in the 
cross-sectional analysis 
 
142 adult patients with supratentorial gliomas included in the 
longitudinal analysis 
 
19 lost to follow up 
 3 died 
 
346 adult patients with intracranial gliomas assessed for 
possible inclusion 
 
173 patients did not 
participate in the study 
 
Figure 1. Flow chart 
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3. 3 Data collection  
Included patients provided written informed consent and completed the EQ-5D 3L 
questionnaire 1-3 days before undergoing surgery. The preoperative KPS were scored on 
admission by a study nurse or the operating surgeon. Patient follow-up was scheduled after 4-
6 weeks (mean 45 days, range 23-150 days).  
Follow-up was based on structured telephone interviews by a study nurse. Postoperative KPS 
scores were assessed based on information from patients and/or relatives from this interview. 
EQ-5D 3L, the same questionnaire as preoperatively, was scored by the patients as part of 
these interviews. Supplementary details were collected from medical records.  
3.3.1 EQ-5D 3L 
EQ-5D 3L is a generic measure of HRQoL developed by the EuroQol Group (77). It is widely 
used in a variety of health conditions and tested and found valid to use in the Norwegian 
population (79). It consists of two parts; a descriptive system (Part I) and a visual analogue 
scale (VAS) (Part II). Part I consists of 5 single-item dimensions including mobility, self-care, 
usual activities, pain/discomfort and anxiety/depression. Each dimension is divided into three 
levels of severity, i.e. “no problem”, “slight problem” or “major problem”, which are 
generating 243 possible combinations of responses. Part II uses VAS to measure health status, 
ranging from worst imaginable health state to best imaginable health state. EQ-5D 3L can be 
presented as a health profile or as a single global health index with a weighted total value for 
HRQoL which are based on a large survey in the UK population (80). EQ-5D 3L index value 
will range from -0,594 to 1, where 1 corresponds to perfect health, and 0 to death. Negative 
values are considered to be worse than death. In the present study, we have calculated our 
MID-estimates from these index values. VAS-score was not analysed.  
3.3.2 KPS 
KPS is a clinical rating of a patient’s functional level. It is a widely utilized measure in 
oncology and a recognized prognostic factor (12, 14, 81). It is much used in neurosurgical 
tumour research and good reliability and validity has been demonstrated (82). In a previous 
study we have demonstrated that EQ-5D 3L index value was significantly correlated with 
KPS (59). Thus, KPS seems to fulfil the criteria for serving as an anchor in patients with 
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glioma (68, 72). With KPS as an anchor in the present study we have made the assumption 
that a change in KPS to one level higher or lower reflects a meaningful change for the patient. 
Table 1 gives a detailed description with an explanation for each level in KPS. In the present 
study KPS-scores ≤60 were merged due to few patients in each group (n≤10). 
Table 1. Karnofsky Performance Status scale*  
Karnofsky score Function 
100 Normal; no complaints; no evidence of disease. 
90 Able to carry on normal activity; minor signs or symptoms of disease 
80 Normal activity with effort; some signs or symptoms of disease 
70 Cares for self; unable to carry on normal activity or do work 
60 Requires occasional assistance, but is able to care for most personal needs 
50 Requires considerable assistance and frequent medical care 
40 Disabled; requires special care and assistance 
30 Severely disabled; hospitalization indicated although death not imminent 
20 Very sick; hospitalization necessary; requires active support treatment 
10 Moribund; fatal processes progressing rapidly 
0 Dead 
* (29) 
4. Ethics and approvals 
All included patients gave their written and informed consent. Data collection was approved 
by the Regional Ethical Committee for Health Region Mid-Norway and adhered to guidelines 
of the Helsinki Declaration (83). 
5. Statistical analyses 
All analyses were done using SPSS statistics, version 19.0. Statistical significance level was 
set to p < 0.05. Q-Q plots were used to test for normal distribution of data. Spearman 
correlation test was performed to examine the correlation between EQ-5D 3L index value and 
KPS.  As recommended by Revicki (72), we used 0.30-0.35 as a correlation threshold to 
define acceptable association between the scores. Since there is no consensus of how much 
data is needed for estimating MID (72) and the responsiveness evaluation is independent of 
sample size (84), no sample size calculation was carried out.  
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5.1 Responsiveness-analyses 
In the responsiveness-analyses, longitudinal data were used and the change in KPS following 
surgery was classified into three groups (unchanged, improved and deteriorated). Through 
bivariate data analysis, a comparison between these changes and the changes in pre- and 
postoperative EQ-5D 3L scores were performed. Responsiveness was evaluated using a 
statistical indicator, the standardized response mean (SRM) (62, 65). Scores were interpreted 
using Cohens criteria for effect sizes (d); 0.20-0.49 is considered as small, 0.50-0.79 as 
moderate and ≥ 0.80 as large (85). A paired sample t-test was used for significance testing.  
5.2 MID-analyses 
To achieve several MID-estimates, and to assess variability both within single patients and 
from patient-to-patient, both longitudinal and cross-sectional data were used in the MID-
analyses. 
In the longitudinal analysis, the change in pre- versus postoperative KPS was compared to the 
change in EQ-5D 3L index values through bivariate data analysis. A change of 10 in KPS was 
considered as a MID-estimate. A paired sample t-test was used to supply this estimate with 
the distribution-based 0.50 SD (standard deviation), a frequently used threshold of 
discrimination for changes in HRQoL for chronic diseases (86). A simple linear regression 
was performed to assess an overall weighted MID-estimate. The unstandardized coefficient 
(b) represents the slope of the curve, i.e. the amount of change in EQ-5D 3L due to a change 
in one unit of KPS.   
In the cross-sectional analysis, the mean preoperative EQ-5D 3L index value was calculated 
for each preoperative KPS score and the differences in between each step were averaged in a 
mean MID-estimate. The 0.50 SD was calculated here as well and a simple linear regression 
was performed. 
5.3 Floor / ceiling effect 
The presence of floor and ceiling effect were studied by reporting the proportions of patients 
with the worst possible score (floor effect) and the best possible score (ceiling effect) at 
baseline. Floor and ceiling effects were considered small if ≤ 15% of patients achieved the 
worst and best health state and large if > 15% of patients achieved these states (87).  
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6. Results 
Baseline characteristics for both the cross-sectional analysis (n=164) and the longitudinal 
analysis (n=142) are summarized in Table 2. The mean age of patients included in the cross-
sectional analysis was 56 years and 54% were men (n=89). High-grade tumours (WHO grade 
III or IV gliomas) were found in 74 % (n=121). Of the procedures, 93% (n=153) were 
resections and 60 % (n= 99) of the included patients underwent primary surgery for their 
glioma.  
The 142 patients included in the longitudinal analysis, had a mean age of 54 years, and 56% 
(n=79) were men. High grade tumours were seen in 71 % (n=101) and 60 % of the patients 
underwent first time glioma surgery (n= 85). Of the procedures, 95 % (n=135) were 
resections.  
In both studied groups (cross-sectional and longitudinal), patients presented with a range of 
symptoms; seizures, headache and cognitive deficits were most common. 
Table 2. Baseline characteristics   
Characteristics Cross-sectional analysis 
n=164 
Longitudinal analysis 
n=142 
 
Age in years, mean ± SD 
 
 
56 (14) 
 
54 (14) 
Gender, n (%) 
 Male 
 Female 
 
 
89 (54) 
75 (46) 
 
79 (56) 
63 (44) 
Histopathology, n (%) 
 Low grade glioma  
 High grade glioma 
 
 
43 (26) 
121 (74) 
 
41 (29) 
101 (71) 
Preoperative symptoms, n (%) 
 Headache 
 Seizures 
 Cognitive deficits 
 Nausea 
 Unsteadiness / ataxia 
 Visual disturbances 
 Aphasia / dysphasia 
 Cranial nerve deficits 
 Motor deficits 
 
 
45 (27) 
60 (37) 
39 (24) 
7 (4) 
32 (20) 
9 (6) 
30 (18) 
11 (7) 
28 (17) 
 
43 (30) 
54 (38) 
33 (23) 
6 (4) 
26 (18) 
6 (4) 
24 (17) 
10 (7) 
23 (16) 
Primary operation, n (%) 
 
99 (60) 85 (60) 
Biopsy only, n (%) 
 
Resection, n (%) 
11 (7) 
 
153 (93) 
7 (5) 
 
135 (95) 
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The correlation between preoperative EQ-5D 3L index value and preoperative KPS was r = 
0.58 and the correlation between postoperative EQ-5D 3L index value and postoperative KPS 
was r = 0.76. KPS had thereby a considerable relationship with EQ-5D 3L and the use of KPS 
as an anchor seemed appropriate.  
6.1 Responsiveness 
Pre- and postoperative changes in EQ-5D 3L index values compared to changes in KPS are 
presented in Table 3. Patients who experienced improvement in KPS levels did not report 
significantly higher EQ-5D 3L index scores with a SRM of 0.04 (p=0.13).  Patient who 
deteriorated in KPS levels after surgery reported a significant drop in EQ-5D 3L index with a 
SRM of 0.72 (p=<0.001). Using Cohen’s criteria for effect sizes, there was no responsiveness 
for patients who improved, but moderate responsiveness for patients who deteriorated. 
Table 3. Changes in EQ-5D 3L index values compared to changes in KPS  
∆KPS n mean SD median min max mean change p SRM 
          
Improved 25 0.08 0.25 0.05 -0.43 0.68 0.01 0.13 0.04 
Unchanged 61 0.07 0.30 0.00 -0.64 0.87    
Deteriorated 56 -0.16 0.32 -0.11 -0.96 0.52 0.23 <0.001 0.72 
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A post-hoc analysis for high-grade gliomas (n=101) is shown in Table 4. In this subgroup, 
there were still no significant changes for improvement and SRM were 0.03 (p=0.32). In 
deteriorated patients, highly significant changes with a SRM of 0.88 were found (p=<0.001). 
Thus, the responsiveness for deterioration was large in this subgroup.  
Table 4. Changes in EQ-5D 3L index values compared to changes in KPS in high-grade gliomas 
∆KPS n mean SD median min max mean change p SRM 
          
Improved 19 0.07 0.29 0.00 -0.43 0.68 0.01 0.32 0.03 
Unchanged 46 0.08 0.33 0.00 -0.64 0.87    
Deteriorated 36 -0.22 0.34 -0.16 -0.96 0.52 -0.30 <0.001 0.88 
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6.2 MID 
In the longitudinal MID-analysis (before vs. after surgery), a mean change in EQ-5D 3L index 
value was found to be 0.15 in the group who had a change of 10 in KPS (Table 5). The mean 
of the 0.50 SDs was 0.15. Using linear regression as an additional anchor-based MID-
estimate, the unstandardized coefficient (b) was 0.07. 
Table 5.  EQ-5D 3L before vs. after surgery anchored by KPS  
∆KPS 
 
n 
mean 
baseline 
mean 
follow up 
mean 
diff 
SD 0.50 SD  
        
10 20 0.75 0.87 0.12 0.26 0.13  
-10 28 0.82 0.65 -0.17 0.32 0.16  
Mean    0.15  0.15 
 
 
        
In the cross-sectional MID-analysis (between patient comparison before surgery), the 
preoperative EQ-5D 3L index values were anchored by the preoperative KPS score (Table 5). 
The mean difference for EQ-5D 3L from KPS level to adjacent KPS level ranged from 0.07 to 
0.18, resulting in an anchor-based mean MID-estimate of 0.14. The distribution-based 0.50 
SDs ranged from 0.08 to 0.16 (mean 0.13). The unstandardized coefficient (b) was 0.13. In a 
post-hoc analysis in patients with high-grade gliomas (n=121) similar MID-estimates was 
found through cross-sectional analysis (Table 7). 
Table 6. Preoperative EQ-5D 3L index values anchored by KPS 
KPS n mean SD median min max mean diff b 0.50 SD 
          
100 35 0.88 0.15 1.00 0.41 1.00   0.08 
90 63 0.81 0.18 0.85 0.16 1.00 0.07  0.09 
80 32 0.65 0.27 0.71 -0.07 1.00 0.16  0.14 
70 16 0.52 0.32 0.63 -0.13 1.00 0.13  0.16 
≤60* 18 0.34 0.32 0.33 -0.24 1.00 0.18  0.16 
Mean  
 
 
     0.14 0.13 0.13 
 
Table 7. Preoperative EQ-5D 3L index values anchored by KPS in high-grade gliomas 
KPS n mean SD median min max mean diff b 0.50 SD 
          
100 13 0.92 0.10 1.00 0.73 1.00   0.05 
90 46 0.80 0.19 0.80 0.16 1.00 0.12  0.10 
80 28 0.65 0.29 0.71 -0.07 1.00 0.15  0.15 
70 16 0.52 0.32 0.63 -0.13 1.00 0.13  0.16 
≤60* 18 0.34 0.32 0.33 -0.24 1.00 0.18  0.16 
Mean  
 
 
     0.15 0.14 0.12 
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The summary of all MID-estimates are presented in Table 8. In longitudinal analyses, the 
MID-estimates ranged from 0.07-0.15. In cross-sectional analyses, the MIDs ranged from 
0.13-0.14.  
Table 8. Summary of MID-estimates 
   mean diff 0,50 SD b 
 
Longitudinal analyses 
 
0.15 
 
0.15 
 
0.07 
 
Cross-sectional analyses 
 
0.14 
 
0.13 
 
0.13 
    
 
6.3 Floor / ceiling effect 
The presence of floor and ceiling effects was explored and is presented in Table 9. There was 
no floor effect for either EQ-5D 3L index value or KPS. However, maximum scores at 
baseline were seen in 24 % (n=40) using EQ-5D 3L and in 21 % (n=35) with KPS. Thus, the 
ceiling effects for both measures were considered large (> 15%). 
When assessing only primary operations (n=99) the ceiling effect remained large for both EQ-
5D 3L and KPS. For only high-grade gliomas (n=121), the ceiling-effect was large for just 
EQ-5D 3L. 
Table 9. Floor / ceiling effects (baseline) 
  Floor, n (%) Ceiling, n (%) 
 
(n=164) 
 
 
 
EQ-5D 3L* 
 
0 (0) 
 
40 (24) 
KPS** 0 (0) 35 (21) 
 
Only primary operations (n=99) EQ-5D 3L* 0 (0) 21 (21) 
KPS** 0 (0) 16 (16) 
   
Only high grade gliomas (n=121) EQ-5D 3L* 0 (0) 25 (21) 
KPS** 0 (0) 13 (11) 
   
*-0.594 vs. 1 **10 vs. 100     
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7. Discussion 
7.1 Main findings 
In this prospective study, we assessed the responsiveness and the MID for EQ-5D 3L index 
value in patients undergoing glioma surgery. We found that EQ-5D 3L is responsive to 
change when the glioma patients are deteriorating functionally but not when they are 
improving. In longitudinal analyses, estimated MID-values ranged from 0.07-0.15. In cross-
sectional analyses, the MIDs ranged from 0.13-0.14. A post hoc-analysis in patients with 
high-grade gliomas revealed similar estimates.  
7.2 Strengths and weaknesses 
Both strengths and weaknesses can be identified in the present study. As recommended, a 
combination of anchor-based and distribution-based methods were used (68, 72). It is 
recommended to calculate the standard error of the measure (SEM) as well, which in turn 
requires internal consistency reliability. For EQ-5D 3L, this is not advisable since the 
questionnaire has single items. Since a confident  MID-value will be based on accumulating 
evidence from multiple measurements (72), several methods were used and both longitudinal 
and cross-sectional data were analysed.  
Using a functional status as an anchor is quite common (70, 88, 89) and because of 
accessibility and interpretability, KPS was chosen for this purpose. By using a single anchor 
we have chosen an individual focused approach (68), while a population focused approach 
using multiple anchors can be recommended (68, 72, 76). An additional anchor should 
perhaps be patient-reported as well, such as “Global rating of change” (67, 90), avoiding 
inter-observer variability and possibility of bias associated with health professionals’ 
evaluation. On the other hand, patients rating their current condition compared to a 
preoperative status are possibly much affected by recall bias.  
The assumption that a change in KPS to one level higher or lower reflects a meaningful 
change for the patients can be debated. A meaningful change for the patients is noticeable 
with respect to function or symptoms or both (65). Since KPS is a functional status, changes 
in cognition and seizure activity may be undetected. This may be the reason for a mean 
improvement of 0.07 in the “unchanged” group in the responsiveness-analysis. Further, it is 
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not self-evident that the observed changes are minimal, and as each step in KPS does not 
reflect a standardized and similar change in function, further heterogeneity is added to the 
material.  
Since glioma is a rare disease, our sample of unselected patients was quite large in this setting 
and it was a prospective study. Although the inclusion rate was somewhat low, we believe 
that there was no systematic skewedness in inclusion, perhaps except for the inability to 
include severely ill patients in a questionnaire based study. The drop-out rate of 13 % among 
included patients is acceptable. Thus, the presented findings should presumably have good 
external validity for elective glioma surgery.    
For capturing the effect of surgery, we chose 4-6 weeks follow up time. This allowed for 
recovery from transient surgically deficits while avoiding the influence of adverse effects of 
any adjuvant treatment. Although this was the intention, occasional patients were assessed 
outside this time window making the follow-up range wider. These occasional patients may 
have been influenced by both steroids and adjuvant treatment.  
To ensure compliance, the baseline data collection of HRQoL date was based on self-
assessment while the follow-up data collection was conducted through telephone interviews. 
This may have an impact on the results since it is demonstrated that self-administered 
questionnaires shows systematically larger HRQoL impairment than interviewer-
administrated questionnaires (91). Since the follow-up data collection for both EQ-5D 3L and 
KPS was done simultaneously, the KPS-score may have been influenced by the patient’s 
answers on EQ-5D 3L as well. In the longitudinal analysis, this may potentially have affected 
both responsiveness and MID-estimates. This justifies the use of cross-sectional 
measurements as additional MID-estimates. 
Challenges exist regarding data collection in glioma patients. Researchers need to consider the 
effects of such obstacles, but they might nevertheless lead to bias. In example, cognitive 
deficits and hearing loss can affect the patient’s perception and they may answer the questions 
incorrectly. Motor deficits and poor vision can complicate their ability to complete a 
questionnaire by self-assessment. Language disorders can be challenging in relation to 
telephone interviews. Assistance from a third part, so-called proxy measurement, is 
sometimes necessary. This will affect the answers as well, but is better than a total absence of 
data (92, 93). 
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7.3 Clinical interpretation 
With the emergence of HRQoL as an outcome in surgical brain tumor research, it is important 
to evaluate different aspects of this outcome parameter. Knowledge of EQ-5D 3Ls ability to 
detect changes in patients undergoing glioma surgery is important when planning and 
designing HRQoL-studies. The MID-value is clearly useful for calculating statistical power 
and for determining sample sizes. MID is also helpful for interpreting results and for 
determining the proportion of patients achieving meaningful changes in HRQoL. However, 
patients may still experience meaningful changes that are either smaller or larger than this 
value. Thus, when using these statistics, it is essential to remain aware of the variability and 
the limitations. 
7.3.1 Responsiveness 
Ideally, EQ-5D 3L should respond to changes both when the QoL improves and when it 
deteriorates. The responsiveness for EQ-5D 3L index value has been explored in several other 
conditions. A variety of different methods have been used, and findings are inconsistent (71, 
94-102).  In the present study, the lack of responsiveness in the glioma patients who improved 
might be explained by the small sample size (n=25) and/or the large ceiling effect for both 
EQ-5D (24 %) and KPS (21 %). The ceiling effect seen in baseline values, means that 
improvement cannot be measured in a high proportion of patients. From studies of other 
diseases, it is known that EQ-5D 3L can suffer from ceiling effects (71, 103). In generic 
instruments, disease specific questions are lacking, which may be relevant in glioma patients 
to detect specific, but diverse symptoms (e.g. dysphasia, cognitive disturbances, visual decline 
etc.). Subtle changes may not be captured and a change in score can therefore not be 
anticipated.  
After the preoperative effect of corticosteroids, few glioma patients significantly improve 
postoperatively. Patients with a significant mass effect due to a high-grade glioma can be an 
exception, but these may be underrepresented in our patient sample since a severe 
preoperative condition both limits the ability to fill out questionnaires and obtain informed 
consent. Also, patients with low-grade glioma with a high seizure burden may experience 
significant improvement postoperatively (104), but the seizure activity is not well captured in 
a function scale like KPS or a crude generic measure. Since KPS is a functional scale assessed 
by health professionals, it is mainly assessing physical improvements or changes in 
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dependency. A patient may well improve in physical function (e.g. KPS) without 
experiencing less pain, improvement of usual activities and/or better psychological status, 
which are reflected together in the EQ-5D 3L index value. Even though some physical and 
functional improvement is seen in some patients after glioma surgery, it is perhaps not 
surprising that the overall QoL is not improving after being diagnosed with incurable brain 
cancer. In most glioma patients, the surgical aim is tumour resection or a biopsy for 
histopathological diagnosis while avoiding a further deterioration. Thus, we believe that the 
demonstrated responsiveness for deterioration is of greater importance when evaluating the 
effects of glioma surgery.  
7.3.2 MID 
MIDs have been estimated for EQ-5D 3L index scores for other oncological conditions and 
ranges between 0.08-0.12 in various cancer patients (70, 71). Another study reported MIDs 
between -0.01-0.14 in 11 different conditions (105). Thus, the demonstrated MID-values in 
glioma patients undergoing surgery are in the upper range compared to findings in these 
studies. Our findings may be influenced by the properties of the anchor chosen. However, 
perhaps a more likely explanation is that glioma is a multifaceted disease.  A functioning 
brain is essential for most aspects of QoL, including personality, mental health, perception, 
physical function and consciousness. The heterogeneity in localization, size, infiltration of 
various functional brain regions, biology, clinical presentation and treatment is considerable. 
Thus, the distribution-based SDs becomes large. In the cross-sectional analysis, patients with 
higher KPS tended to have lower MID-estimates. Because of less heterogeneity in patients 
with “normal functions”, a MID-value between 0.07-0.09 may be relevant for patients with a 
KPS level of 90-100.  
7.3.3 EQ-5D 3L as an outcome in glioma surgery 
With an unfavourable prognosis of high-grade gliomas and since surgery is no cure, the 
patients’ HRQoL should be a primary concern. Patients with low-grade gliomas may live for 
years, even without surgery. Preserving their function and HRQoL is therefore of outermost 
importance. The goal of surgery is to achieve extensive resections since this is associated with 
improved survival (13, 14, 16, 17). This is the main potential benefit of surgery and is best 
evaluated with assessment of resection grades and survival. However, this potential benefit is 
to be achieved with preservation of function and HRQoL. The benefits with using HRQoL 
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rather than functional scales as KPS rated by health professionals is the prospective nature of 
HRQoL together with the avoidance of assessment bias. In our view, results on patients well-
being achieved this way are far more trustworthy than the common retrospective results 
assessed by the involved health-care providers (43-46). 
Disease-specific HRQoL-instruments are generally more sensitive than generic HRQoL-
instruments (48) and are likely to be more responsive to changes. A specifically designed 
disease-specific instrument for glioma surgery is thereby desired, but is currently lacking. The 
disease-specific instrument EORTC QLQ-C30 (53)  has a brain module to secure relevance 
and sensitivity  in brain tumor patients and are commonly used in glioma patients (47, 52, 54). 
Unfortunately for researchers evaluating surgery, this questionnaire is mainly designed to 
detect the effects and side effects of adjuvant therapy such as radiotherapy and chemotherapy. 
Since the brain is the most complex of all organs, a possible disease-specific instrument 
designed to assess symptoms, functions and quality of life in such diverse patients will need 
to be extremely extensive to detect all facets of brain functions. Such an extensive and 
complicated instrument will probably be problematic for many dependent patients with 
cognitive deficits. Thus, a simple instrument like EQ-5D 3L may be a more preferable choice, 
despite ceiling effects and the observed lack of responsiveness for improvement. In fact, 
Krabbe et al. compared the responsiveness for EQ-5D 3L in patients with liver metastases and 
found similar results for EQ-5D 3L index value and EORTC-QLQ-C30 global health scale 
(106). Using EQ-5D 3L may enhance patient perception and ensure compliance and 
usefulness in unselected patients. Since it is frequently used in other conditions, it allows for 
comparisons between patient groups and can also be used for calculating quality-adjusted life 
years, QALYs, which facilitate economic evaluations (107). Since EQ-5D 3L is responsive in 
patients who deteriorate, and deterioration in HRQoL shortly after surgery is associated with 
impaired survival (60), EQ-5D 3L may function well as a quality indicator in glioma surgery. 
7.4 Implications for future research 
As validation of HRQoL instruments is a never-ending process, accumulating evidence from 
multiple studies is required. Since an appropriate second anchor was not available in this 
study, future studies should include multiple anchors, including some patient-reported. In the 
present study we assessed only EQ-5D 3L index value. Changes in the other part of the 
questionnaire, EQ-VAS, could be particularly interesting in glioma patients due to their subtle 
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changes and diverse symptoms. EQ-VAS has been found to be more strongly associated with 
changes in mental aspects of health, whereas the EQ-5D index value is more strongly related 
to changes in measures of disability and activities to daily living (108). An extended version 
of EQ-5D, called EQ-5D 5L, has recently been developed by the EuroQol Group (109). In 
this questionnaire, each dimension is divided into five levels of severity instead of three. This 
questionnaire is promising with respect to simplicity, sensitivity and perhaps ceiling effects 
and a utilization and evaluation in patients undergoing glioma surgery could be of interest. 
8. Conclusions 
To our knowledge, this is the first study assessing the responsiveness and MID-value for EQ-
5D 3L index value in patients undergoing glioma surgery. EQ-5D 3L is responsive to changes 
when the patients are deteriorating functionally but not responsive when the patients are 
improving. The MID-values for EQ-5D 3L index score range from 0.07-0.15. This is in the 
upper range when compared to MID-values for other conditions, possibly related to the 
clinical heterogeneity in glioma patients. Since EQ-5D 3L is responsive in patients who 
deteriorate, and previous findings have shown that deterioration in HRQoL shortly after 
surgery is associated with impaired survival, EQ-5D 3L may function well as a quality 
indicator in glioma surgery. 
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